Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Dermatology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 160 articles: HTML format

Single Articles

June 2024
1. KAMEI M, Matsuo K, Yoshida Y, Shimada K, et al
   Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
   Int J Cancer. 2024;154:2176-2188.
   PubMed     Abstract available
   
   
   May 2024
2. HAN X, Liu Y, Zhang S, Li L, et al
   Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
   Int J Cancer. 2024;154:1802-1813.
   PubMed     Abstract available
   
   
   April 2024
3. KNUUTILA JS, Riihila P, Nissinen L, Heiskanen L, et al
   Cancer-associated fibroblast activation predicts progression, metastasis, and prognosis of cutaneous squamous cell carcinoma.
   Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34957.
   PubMed     Abstract available
   
   
   
4. FROHLICH LM, Villar-Miyar A, Heintze T, Sauer B, et al
   PARP1 expression predicts PARP inhibitor sensitivity and correlates with metastatic potential and overall survival in melanoma.
   Int J Cancer. 2024 Apr 15. doi: 10.1002/ijc.34947.
   PubMed     Abstract available
   
   
   
5. PEILA R, Rohan TE
   Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study.
   Int J Cancer. 2024;154:1191-1203.
   PubMed     Abstract available
   
   
   March 2024
6. BAANDRUP L, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
   Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma.
   Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34927.
   PubMed     Abstract available
   
   
   
7. SCHMIDT ME, Maurer T, Behrens S, Seibold P, et al
   Cancer-related fatigue: Towards a more targeted approach based on classification by biomarkers and psychological factors.
   Int J Cancer. 2024;154:1011-1018.
   PubMed     Abstract available
   
   
   
8. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
   Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
   Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
   PubMed     Abstract available
   
   
   
9. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
   Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
   Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
   PubMed     Abstract available
   
   
   
10. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    PubMed     Abstract available
    
    
    February 2024
11. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    PubMed     Abstract available
    
    
    
12. SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al
    Age-related phenotypes in breast cancer: A population-based study.
    Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863.
    PubMed     Abstract available
    
    
    
13. CHELLADURAI M, Xu D, Izraely S, Ben-Menachem S, et al
    A heterodimer of alpha and beta hemoglobin chains functions as an innate anticancer agent.
    Int J Cancer. 2024;154:561-572.
    PubMed     Abstract available
    
    
    January 2024
14. VAN DUIN IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, et al
    A prediction model for response to immune checkpoint inhibition in advanced melanoma.
    Int J Cancer. 2024 Jan 31. doi: 10.1002/ijc.34853.
    PubMed     Abstract available
    
    
    
15. RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al
    SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
    Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859.
    PubMed     Abstract available
    
    
    
16. SHARMA MP, Shukla S, Misra G
    Recent advances in breast cancer cell line research.
    Int J Cancer. 2024 Jan 17. doi: 10.1002/ijc.34849.
    PubMed     Abstract available
    
    
    
17. JENSEN HAR, Horsbol TA, Thygesen LC, Davidsen M, et al
    Variations in the agreement of self-reported cancer: A Danish nationwide study.
    Int J Cancer. 2024;154:217-225.
    PubMed     Abstract available
    
    
    
18. CHEN H, Yang G, Ma J
    Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
    Int J Cancer. 2024 Jan 12. doi: 10.1002/ijc.34848.
    PubMed     Abstract available
    
    
    
19. PLASS C
    Alert regarding "Social inequalities in treatment receipt for childhood cancers in Ireland: A population-based analysis. Michal Molcho, Audrey A. Thomas, Paul M. Walsh, Roderick Skinner, Linda Sharp. Int J Cancer 2022 Mar 15;150(6):941-951. https://do
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34840.
    PubMed    
    
    
    
20. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available
    
    
    December 2023
21. DINTER L, Karitzky PC, Schulz A, Wurm AA, et al
    BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.
    Int J Cancer. 2023 Dec 11. doi: 10.1002/ijc.34807.
    PubMed     Abstract available
    
    
    November 2023
22. HUERGO-BANOS C, Velasco V, Garate J, Fernandez R, et al
    Lipid fingerprint-based histology accurately classifies nevus, primary melanoma, and metastatic melanoma samples.
    Int J Cancer. 2023 Nov 20. doi: 10.1002/ijc.34800.
    PubMed     Abstract available
    
    
    
23. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
    Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
    Int J Cancer. 2023;153:1784-1796.
    PubMed     Abstract available
    
    
    
24. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    PubMed     Abstract available
    
    
    
25. YANG F, Sun D, Ding C, Xia C, et al
    Global patterns of cancer transitions: A modelling study.
    Int J Cancer. 2023;153:1612-1622.
    PubMed     Abstract available
    
    
    October 2023
26. ROSAS JC, Aguado-Barrera ME, Azria D, Briers E, et al
    Reply to: Comments on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34772.
    PubMed    
    
    
    
27. CHEN H, Feng L
    Comment on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34770.
    PubMed    
    
    
    
28. YU Z, Dong X, Song M, Xu A, et al
    Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769.
    PubMed     Abstract available
    
    
    
29. RUGO HS, Liu X, Li B, McRoy L, et al
    Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
    Int J Cancer. 2023 Oct 13. doi: 10.1002/ijc.34748.
    PubMed     Abstract available
    
    
    
30. AFSHAR N, Dashti SG, Mar V, Te Marvelde L, et al
    Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data.
    Int J Cancer. 2023 Oct 12. doi: 10.1002/ijc.34752.
    PubMed     Abstract available
    
    
    
31. ZEVERIJN LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, et al
    Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Int J Cancer. 2023;153:1413-1422.
    PubMed     Abstract available
    
    
    September 2023
32. ZHANG J, Zhang F, Porter KI, Dakup PP, et al
    Telomere dysfunction in Tert knockout mice delays Braf(V600E) -induced melanoma development.
    Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34713.
    PubMed     Abstract available
    
    
    
33. HYUNG J, Lee SB, Kim J, Kim HJ, et al
    21-gene expression assay and clinical outcomes of premenopausal patients with hormone receptor-positive breast cancer.
    Int J Cancer. 2023 Sep 17. doi: 10.1002/ijc.34728.
    PubMed     Abstract available
    
    
    
34. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    
35. LIU J, He M, Ou K, Wang X, et al
    Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
    Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34717.
    PubMed     Abstract available
    
    
    August 2023
36. LIGORIO F, Lobefaro R, Fuca G, Provenzano L, et al
    Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34701.
    PubMed     Abstract available
    
    
    
37. MOORAD R, Kasonkanji E, Gumulira J, Gondwe Y, et al
    A prospective cohort study identifies two types of HIV+ Kaposi Sarcoma lesions: proliferative and inflammatory.
    Int J Cancer. 2023 Aug 21. doi: 10.1002/ijc.34689.
    PubMed     Abstract available
    
    
    
38. MAKHETHA M, Chabilal N, Aldous C
    Recent trends in hereditary breast cancer incidence by race and age in KwaZulu-Natal, South Africa: An 11-year single-centre retrospective study (2011-2021).
    Int J Cancer. 2023 Aug 14. doi: 10.1002/ijc.34687.
    PubMed     Abstract available
    
    
    
39. ALLALI S, Carton M, Everhard S, Rivera S, et al
    CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancer.
    Int J Cancer. 2023 Aug 12. doi: 10.1002/ijc.34664.
    PubMed     Abstract available
    
    
    
40. LI Y, Tong Z, Wu X, Ouyang Q, et al
    Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
    Int J Cancer. 2023 Aug 6. doi: 10.1002/ijc.34676.
    PubMed     Abstract available
    
    
    July 2023
41. ROCHE ME, Ko YH, Domingo-Vidal M, Lin Z, et al
    TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer.
    Int J Cancer. 2023 Jul 27. doi: 10.1002/ijc.34660.
    PubMed     Abstract available
    
    
    
42. KRETSCHMER L, Bernhard L, Leha A, Kromer C, et al
    Checkpoint blockade and BRAF/MEK therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998-2009 and 2010-2017.
    Int J Cancer. 2023;153:380-388.
    PubMed     Abstract available
    
    
    
43. ROSAS JC, Aguado-Barrera ME, Azria D, Briers E, et al
    (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.
    Int J Cancer. 2023 Jul 5. doi: 10.1002/ijc.34640.
    PubMed     Abstract available
    
    
    June 2023
44. BEDDOK A, Mouren V, Cottu P, Laki F, et al
    Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Int J Cancer. 2023 Jun 28. doi: 10.1002/ijc.34562.
    PubMed     Abstract available
    
    
    
45. SCHMIDT ME, Chong M, Klassen O, Wiskemann J, et al
    Longitudinal associations of bioelectrical phase angle and fatigue in breast cancer patients.
    Int J Cancer. 2023 Jun 20. doi: 10.1002/ijc.34630.
    PubMed     Abstract available
    
    
    
46. PAGANO C, di Zazzo E, Avilia G, Savarese B, et al
    Advances in "adiponcosis": Insights in the inner mechanisms at the base of adipose and tumour tissues interplay.
    Int J Cancer. 2023;152:2464-2473.
    PubMed     Abstract available
    
    
    
47. JIANG M, Liu J, Li Q, Xu B, et al
    The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status.
    Int J Cancer. 2023 Jun 14. doi: 10.1002/ijc.34570.
    PubMed     Abstract available
    
    
    
48. ROMANENS L, Chaskar P, Marcone R, Ryser S, et al
    Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics.
    Int J Cancer. 2023 Jun 12. doi: 10.1002/ijc.34620.
    PubMed     Abstract available
    
    
    
49. FRAGALE A, Stellacci E, Romagnoli G, Licursi V, et al
    Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
    Int J Cancer. 2023 Jun 9. doi: 10.1002/ijc.34602.
    PubMed     Abstract available
    
    
    
50. RAJKOVIC SM, Charalambous MP, Charalambous CP, Simic LD, et al
    Higher rate of progesterone receptor positivity in skeletal metastases of breast cancer with a pathological fracture vs those without fracture.
    Int J Cancer. 2023 Jun 2. doi: 10.1002/ijc.34605.
    PubMed     Abstract available
    
    
    
51. WITHROW DR, Nicholson BD, Morris EJA, Wong ML, et al
    Age-related differences in cancer relative survival in the United States: A SEER-18 analysis.
    Int J Cancer. 2023;152:2283-2291.
    PubMed     Abstract available
    
    
    
52. GABRIELSON M, Hammarstrom M, Backlund M, Bergqvist J, et al
    Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
    Int J Cancer. 2023;152:2362-2372.
    PubMed     Abstract available
    
    
    May 2023
53. KUANG X, Luo Z, Sun Z, Hu J, et al
    Distinct invasive patterns in situ between estrogen receptor-positive and triple-negative breast cancer through the intraductal tracking of carbon nanoparticles.
    Int J Cancer. 2023 May 31. doi: 10.1002/ijc.34611.
    PubMed     Abstract available
    
    
    
54. SONG H, Jung YS, Tran TXM, Moon CM, et al
    Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study.
    Int J Cancer. 2023 May 29. doi: 10.1002/ijc.34573.
    PubMed     Abstract available
    
    
    
55. GRIGUOLO G, Aldegheri V, Bottosso M, Pittaro A, et al
    Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients.
    Int J Cancer. 2023 May 27. doi: 10.1002/ijc.34571.
    PubMed     Abstract available
    
    
    
56. SYLEOUNI ME, Karavasiloglou N, Manduchi L, Wanner M, et al
    Predicting second breast cancer among women with primary breast cancer using machine learning algorithms, a population-based observational study.
    Int J Cancer. 2023 May 27. doi: 10.1002/ijc.34568.
    PubMed     Abstract available
    
    
    
57. KRISTIANSEN MF, Mikkelsen RM, Kristiansdottir T, Andorsdottir G, et al
    Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries.
    Int J Cancer. 2023;152:2090-2098.
    PubMed     Abstract available
    
    
    
58. SUNDQVIST BZ, Kilpinen SK, Bohling TO, Koljonen VSK, et al
    Transcriptomic analyses reveal three distinct molecular subgroups of Merkel cell carcinoma with differing prognoses.
    Int J Cancer. 2023;152:2099-2108.
    PubMed     Abstract available
    
    
    April 2023
59. KANNAN S, Cheng VWT
    Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends.
    Int J Cancer. 2023 Apr 25. doi: 10.1002/ijc.34542.
    PubMed     Abstract available
    
    
    
60. RANTALA JNJ, Heikkinen SMM, Hirvonen EM, Tanskanen T, et al
    Familial aggregation of early-onset cancers in early-onset breast cancer families.
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34538.
    PubMed     Abstract available
    
    
    
61. 
    Erratum to "Clinical value of routine [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography scans as a decision tool for early immunotherapy discontinuation in advanced melanoma".
    Int J Cancer. 2023 Apr 12. doi: 10.1002/ijc.34534.
    PubMed    
    
    
    
62. KREGTING LM, van Ravesteyn NT, Chootipongchaivat S, Heijnsdijk EAM, et al
    Cumulative risks of false positive recall and screen-detected breast cancer after multiple screening examinations.
    Int J Cancer. 2023 Apr 10. doi: 10.1002/ijc.34530.
    PubMed     Abstract available
    
    
    
63. VAN STEENHOVEN JEC, van Maaren MC, Verreck EEF, Schipper RJ, et al
    Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
    Int J Cancer. 2023;152:1378-1387.
    PubMed     Abstract available
    
    
    
64. WAGENER R, Walter C, Auer F, Alzoubi D, et al
    The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
    Int J Cancer. 2023;152:1388-1398.
    PubMed     Abstract available
    
    
    March 2023
65. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    PubMed     Abstract available
    
    
    
66. QIN Z, Li J, Tam B, Sinha S, et al
    Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
    Int J Cancer. 2023;152:1159-1173.
    PubMed     Abstract available
    
    
    
67. HEIKKINEN S, Demers PA, Hansen J, Jakobsen J, et al
    Incidence of cancer among Nordic police officers.
    Int J Cancer. 2023;152:1124-1136.
    PubMed     Abstract available
    
    
    
68. ZHOU J, Li Y, Qiu T, Gong X, et al
    Long-term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges.
    Int J Cancer. 2023 Mar 14. doi: 10.1002/ijc.34509.
    PubMed     Abstract available
    
    
    
69. CARDOSO R, Hoffmeister M, Brenner H
    Breast cancer screening programmes and self-reported mammography use in European countries.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34494.
    PubMed     Abstract available
    
    
    February 2023
70. VAN DUIN IAJ, Elias SG, van den Eertwegh AJM, de Groot JWB, et al
    Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34479.
    PubMed     Abstract available
    
    
    
71. DE MEZA MM, Blokx WAM, Bonenkamp HJ, Blank CU, et al
    Adjuvant Treatment of In-Transit Melanoma: Narrowing the Knowledge Gap Left by Clinical Trials.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34485.
    PubMed     Abstract available
    
    
    
72. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    PubMed     Abstract available
    
    
    
73. LIU S, van Dinther M, Hagenaars SC, Gu Y, et al
    Differential Optineurin expression controls TGFbeta signaling and is a key determinant for metastasis of triple negative breast cancer.
    Int J Cancer. 2023 Feb 23. doi: 10.1002/ijc.34483.
    PubMed     Abstract available
    
    
    
74. XIA C, Yu XQ, Chen W
    Measuring population-level cure patterns for cancer patients in the United States.
    Int J Cancer. 2023;152:738-748.
    PubMed     Abstract available
    
    
    
75. JIA G, Yang Y, Ping J, Xu S, et al
    Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.
    Int J Cancer. 2023 Feb 13. doi: 10.1002/ijc.34472.
    PubMed     Abstract available
    
    
    
76. DE FALCO V, Suarato G, Napolitano R, Argenziano G, et al
    Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: data from two Academic Italian Institutions.
    Int J Cancer. 2023 Feb 8. doi: 10.1002/ijc.34462.
    PubMed     Abstract available
    
    
    
77. GETU MA, Chen C, Addissie A, Seife E, et al
    The effect of cognitive behavioural therapy integrated with activity pacing on cancer-related fatigue, depression and quality of life among patients with breast cancer undergoing chemotherapy in Ethiopia: a randomised clinical trial.
    Int J Cancer. 2023 Feb 6. doi: 10.1002/ijc.34452.
    PubMed     Abstract available
    
    
    
78. MOTLHALE M, Muchengeti M, Bradshaw D, Chen WC, et al
    Kaposi sarcoma-associated herpesvirus, HIV-1 and Kaposi sarcoma risk in black South Africans diagnosed with cancer during antiretroviral treatment rollout.
    Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34454.
    PubMed     Abstract available
    
    
    January 2023
79. GONZALEZ-CALLEJO P, Gener P, Diaz-Riascos ZV, Conti S, et al
    Extracellular vesicles secreted by triple negative breast cancer stem cells trigger pre-metastatic niche remodeling and metastatic growth in the lungs.
    Int J Cancer. 2023 Jan 27. doi: 10.1002/ijc.34447.
    PubMed     Abstract available
    
    
    
80. XU B, Ma F, Wang T, Wang S, et al
    A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
    Int J Cancer. 2023 Jan 9. doi: 10.1002/ijc.34424.
    PubMed     Abstract available
    
    
    
81. KAR A, Medatwal N, Rajput K, Mandal S, et al
    Unique Sphingolipid Signature Identifies Luminal and Triple-Negative Breast Cancer Subtypes.
    Int J Cancer. 2023 Jan 5. doi: 10.1002/ijc.34423.
    PubMed     Abstract available
    
    
    December 2022
82. BOUCHERON P, Anele A, Offiah AU, Zietsman A, et al
    Reproductive history and breast cancer survival: findings from the African Breast Cancer - Disparities in Outcomes cohort and implications of Africa's fertility transition on breast cancer prognosis.
    Int J Cancer. 2022 Dec 22. doi: 10.1002/ijc.34411.
    PubMed     Abstract available
    
    
    November 2022
83. HEY J, Halperin C, Hartmann M, Mayer S, et al
    DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors, and prognostic value relevant to triple-negative breast cancer patients.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34364.
    PubMed     Abstract available
    
    
    
84. LIN M, Jin Y, Lv H, Hu X, et al
    Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34365.
    PubMed     Abstract available
    
    
    
85. JAEHN P, Bergholz A, Holmberg C
    Regional inequalities of tumour size at diagnosis in Germany: An ecological study in eight federal states.
    Int J Cancer. 2022;151:1684-1695.
    PubMed     Abstract available
    
    
    
86. ARMAROLI P, Frigerio A, Correale L, Ponti A, et al
    A randomised controlled trial of digital breast tomosynthesis vs digital mammography as primary screening tests: Screening results over subsequent episodes of the Proteus Donna study.
    Int J Cancer. 2022;151:1778-1790.
    PubMed     Abstract available
    
    
    
87. ALCARAZ LB, Mallavialle A, Mollevi C, Boissiere-Michot F, et al
    SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34345.
    PubMed     Abstract available
    
    
    
88. CAIRAT M, Pottegard A, Olesen M, Dossus L, et al
    Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34343.
    PubMed     Abstract available
    
    
    October 2022
89. MANOOCHEHRI M, Borhani N, Gerhauser C, Assenov Y, et al
    DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy.
    Int J Cancer. 2022 Oct 28. doi: 10.1002/ijc.34337.
    PubMed     Abstract available
    
    
    
90. CARIOLOU M, Abar L, Aune D, Balducci K, et al
    Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34324.
    PubMed     Abstract available
    
    
    
91. TSILIDIS KK, Cariolou M, Becerra-Tomas N, Balducci K, et al
    Postdiagnosis body fatness, recreational physical activity, dietary factors and breast cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34320.
    PubMed     Abstract available
    
    
    
92. CHAN DSM, Vieira R, Abar L, Aune D, et al
    Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34322.
    PubMed     Abstract available
    
    
    
93. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available
    
    
    
94. LYNGE E, Vjeborg I, Lillholm M, Nielsen M, et al
    Breast Density and Risk of Breast Cancer.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34316.
    PubMed     Abstract available
    
    
    September 2022
95. KANKURI-TAMMILEHTO M, Tervasmaki A, Kraatari-Tiri M, Rahikkala E, et al
    ATM c.7570G>C is a high-risk allele for breast cancer.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34305.
    PubMed     Abstract available
    
    
    
96. MAILLIEZ A, D'Hondt V, Lusque A, Caron O, et al
    Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34304.
    PubMed     Abstract available
    
    
    
97. WATTS K, Wills C, Madi A, Palles C, et al
    Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    Int J Cancer. 2022;151:957-966.
    PubMed     Abstract available
    
    
    
98. WU J, Tan X
    The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
    Int J Cancer. 2022;151:888-896.
    PubMed     Abstract available
    
    
    August 2022
99. SEEFRIED F, Haller L, Fukuda S, Thongmao A, et al
    Nuclear AREG affects a low-proliferative phenotype and contributes to drug resistance of melanoma.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34254.
    PubMed     Abstract available
    
    
    
100. MAHAMAT-SALEH Y, Al-Rahmoun M, Severi G, Ghiasvand R, et al
     Baseline and lifetime alcohol consumption and risk of skin cancer in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC).
     Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34253.
     PubMed     Abstract available
     
     
     
101. LOK SW, De Boer R, Baron-Hay S, Button P, et al
     Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
     Int J Cancer. 2022 Aug 16. doi: 10.1002/ijc.34245.
     PubMed     Abstract available
     
     
     
102. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
     Reply to: Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
     Int J Cancer. 2022;151:651-652.
     PubMed    
     
     
     
103. BRAILLON A
     Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
     Int J Cancer. 2022;151:649-650.
     PubMed    
     
     
     
104. PEILA R, Lane DS, Shadyab AH, Saquib N, et al
     Healthy lifestyle index and the risk of ductal carcinoma in situ of the breast in the Women's Health Initiative.
     Int J Cancer. 2022;151:526-538.
     PubMed     Abstract available
     
     
     July 2022
105. MATTA M, Deubler E, Chajes V, Vozar B, et al
     Circulating plasma phospholipid fatty acid levels and breast cancer risk in the Cancer Prevention Study-II Nutrition Cohort.
     Int J Cancer. 2022 Jul 18. doi: 10.1002/ijc.34216.
     PubMed     Abstract available
     
     
     
106. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
     Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
     Int J Cancer. 2022;151:287-296.
     PubMed     Abstract available
     
     
     
107. ROELANDT P, Droogne W, Voros G, Van Aelst L, et al
     Are heart transplant recipients more at risk for anal squamous carcinoma than other solid organ transplant recipients?
     Int J Cancer. 2022;151:156-157.
     PubMed    
     
     
     
108. BASSETT JK, MacInnis RJ, Yang Y, Hodge AM, et al
     Alcohol intake trajectories during the life course and risk of alcohol-related cancer: A prospective cohort study.
     Int J Cancer. 2022;151:56-66.
     PubMed     Abstract available
     
     
     June 2022
109. ZAREMBA A, Jansen P, Murali R, Mayakonda A, et al
     Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
     Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34187.
     PubMed     Abstract available
     
     
     
110. YARMOLINSKY J, Amos CI, Hung RJ, Moreno V, et al
     Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
     Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34180.
     PubMed     Abstract available
     
     
     
111. KARAVASILOGLOU N, Pestoni G, Kuhn T, Rohrmann S, et al
     Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank.
     Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34183.
     PubMed     Abstract available
     
     
     
112. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
     Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
     Int J Cancer. 2022;150:1978-1986.
     PubMed     Abstract available
     
     
     
113. RATOSA I, Dobnikar N, Bottosso M, Dieci MV, et al
     Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort.
     Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34135.
     PubMed     Abstract available
     
     
     
114. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
     Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
     Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
     PubMed     Abstract available
     
     
     
115. WU Z, Byrd DA, Wan Y, Ansong D, et al
     The oral microbiome and breast cancer and non-malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study.
     Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34145.
     PubMed     Abstract available
     
     
     
116. FRIMAN TK, Jaamaa-Holmberg S, Aberg F, Helantera I, et al
     Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland.
     Int J Cancer. 2022;150:1779-1791.
     PubMed     Abstract available
     
     
     May 2022
117. MARSHALL VA, Fisher NC, Goodman CA, Cornejo Castro EM, et al
     Systematic Analysis of Kaposi's Sarcoma-associated Herpesvirus Genomes from a Kaposi's Sarcoma (KS) Case-Control Study in Cameroon: Evidence of Dual Infections but No Association Between Viral Sequence Variation and KS Risk.
     Int J Cancer. 2022 May 24. doi: 10.1002/ijc.34136.
     PubMed     Abstract available
     
     
     April 2022
118. ALLALI S, Carton M, Sarrade T, Querel O, et al
     CANTO-RT: Skin toxicities evaluation of a multicenter large prospective cohort of irradiated patients for early-stage breast cancer.
     Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34057.
     PubMed     Abstract available
     
     
     
119. TRAN TXM, Kim S, Song H, Park B, et al
     Mammographic Breast Density, Body Mass Index, and Risk of Breast Cancer in Korean Women Aged 75 Years and Older.
     Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34038.
     PubMed     Abstract available
     
     
     
120. CLAYTON B, Muneeb F, Hughes MCB, Grant ME, et al
     Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: a multi-centre study.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34020.
     PubMed     Abstract available
     
     
     
121. CHEN F, Wen W, Long J, Shu X, et al
     Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34026.
     PubMed     Abstract available
     
     
     
122. BOUWER NI, Steenbruggen TG, Rier HN, Kitzen JJ, et al
     The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34024.
     PubMed     Abstract available
     
     
     
123. XIU M, Zhang P, Wang X, Fan Y, et al
     Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant versus standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: a prospective cohort study with propensity-matched analysis.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34022.
     PubMed     Abstract available
     
     
     
124. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
     Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
     Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
     PubMed     Abstract available
     
     
     March 2022
125. XIE Y, Zhang Y, Xie K, Zhong X, et al
     Impact of time to initiation of postoperative radiotherapy after neoadjuvant chemotherapy on the prognosis of breast cancer: a retrospective cohort study in China.
     Int J Cancer. 2022 Mar 25. doi: 10.1002/ijc.34003.
     PubMed     Abstract available
     
     
     
126. WATT GP, Knight JA, Nguyen TL, Reiner AS, et al
     Association of contralateral breast cancer risk with mammographic density defined at higher-than-conventional intensity thresholds.
     Int J Cancer. 2022 Mar 22. doi: 10.1002/ijc.34001.
     PubMed     Abstract available
     
     
     February 2022
127. AYENI OA, O'Neil DS, Pumpalova YS, Chen WC, et al
     Impact of HIV infection on Survival among Women with Stage I-III Breast Cancer: Results from the South African Breast Cancer and HIV Outcomes Study.
     Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33981.
     PubMed     Abstract available
     
     
     
128. HAFSTAETH V, Sokilde R, Hakkinen J, Larsson M, et al
     Regulatory networks and 5' partner usage of miRNA host gene fusions in breast cancer.
     Int J Cancer. 2022 Feb 19. doi: 10.1002/ijc.33972.
     PubMed     Abstract available
     
     
     
129. JOHANSSON A, Yiu-Lin Yu N, Iftimi A, Tobin NP, et al
     Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature.
     Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33969.
     PubMed     Abstract available
     
     
     
130. HA MJ, Raghavendra AS, Kettner NM, Qiao W, et al
     Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study.
     Int J Cancer. 2022 Feb 8. doi: 10.1002/ijc.33959.
     PubMed     Abstract available
     
     
     
131. FLUGELMAN AA, Burton A, Keinan-Boker L, Stein N, et al
     Correlation between cumulative mammographic density and age - specific incidence of breast cancer: a bi-ethnic study in israel.
     Int J Cancer. 2022 Feb 6. doi: 10.1002/ijc.33957.
     PubMed     Abstract available
     
     
     January 2022
132. IBRAHIM KHALIL A, Franceschi S, de Martel C, Bray F, et al
     Burden of Kaposi sarcoma according to HIV status: a systematic review and global analysis.
     Int J Cancer. 2022 Jan 27. doi: 10.1002/ijc.33951.
     PubMed     Abstract available
     
     
     
133. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
     Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales.
     Int J Cancer. 2022 Jan 20. doi: 10.1002/ijc.33938.
     PubMed     Abstract available
     
     
     
134. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
     Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
     Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
     PubMed     Abstract available
     
     
     
135. ELLEBAEK E, Schina A, Andersen R, Hendel HW, et al
     Clinical value of routine FDG-PET scans as a decision tool for early immunotherapy discontinuation in advanced melanoma.
     Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33926.
     PubMed     Abstract available
     
     
     
136. GOTTSCHAU M, Bens A, Friis S, Cronin-Fenton D, et al
     Use of beta-blockers and risk of contralateral breast cancer.
     Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33923.
     PubMed     Abstract available
     
     
     
137. AAMDAL E, Jacobsen KD, Straume O, Kersten C, et al
     Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
     Int J Cancer. 2022;150:100-111.
     PubMed     Abstract available
     
     
     December 2021
138. ZHOU W, Jiang Y, Xu Y, Wang Y, et al
     Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: a propensity-score matched cohort study.
     Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33919.
     PubMed     Abstract available
     
     
     
139. ABASCAL MF, Elia A, Alvarez M, Pataccini G, et al
     Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
     Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33913.
     PubMed     Abstract available
     
     
     
140. WEGE AK, Rom-Jurek EM, Jank P, Denkert C, et al
     mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
     Int J Cancer. 2021 Dec 20. doi: 10.1002/ijc.33911.
     PubMed     Abstract available
     
     
     
141. PARK B
     Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
     Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
     PubMed     Abstract available
     
     
     
142. ASCIERTO PA, Orlova K, Grignani G, Dudzisz-Sledz M, et al
     Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.
     Int J Cancer. 2021;149:1926-1934.
     PubMed     Abstract available
     
     
     November 2021
143. LOAP P, Loirat D, Berger F, Cao K, et al
     Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial.
     Int J Cancer. 2021;149:1828-1832.
     PubMed     Abstract available
     
     
     
144. DUSINGIZE JC, Law MH, Pandeya N, Neale RE, et al
     Genetically determined cutaneous nevi and risk of cancer.
     Int J Cancer. 2021 Nov 14. doi: 10.1002/ijc.33874.
     PubMed     Abstract available
     
     
     
145. KIM DS, Ahn HS, Kim HJ
     Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
     Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
     PubMed     Abstract available
     
     
     
146. MARLEY AR, Li M, Champion VL, Song Y, et al
     Citrus-Gene Interaction and Melanoma Risk in the UK Biobank.
     Int J Cancer. 2021 Nov 1. doi: 10.1002/ijc.33862.
     PubMed     Abstract available
     
     
     October 2021
147. LAI X, Zhou J, Wessely A, Heppt M, et al
     A disease network-based deep learning approach for characterizing melanoma.
     Int J Cancer. 2021 Oct 29. doi: 10.1002/ijc.33860.
     PubMed     Abstract available
     
     
     
148. WANG C, Gu K, Wang F, Cai H, et al
     Nut consumption in association with overall mortality and recurrence/disease-specific mortality among long-term breast cancer survivors.
     Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33824.
     PubMed     Abstract available
     
     
     
149. YE C, Zhou W, Wang F, Yin G, et al
     Prognostic Value of GILT Expression in Female Patients Diagnosed with Breast Cancer.
     Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33843.
     PubMed     Abstract available
     
     
     
150. VAN NOT OJ, van Breeschoten J, van den Eertwegh AJM, Hilarius DL, et al
     The unfavorable effects of COVID-19 on Dutch advanced melanoma care.
     Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33833.
     PubMed     Abstract available
     
     
     September 2021
151. ZHANG L, Wu ZY, Li J, Lin Y, et al
     Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
     Int J Cancer. 2021 Sep 30. doi: 10.1002/ijc.33830.
     PubMed     Abstract available
     
     
     
152. POISEUIL M, Tron L, Woronoff AS, Tretarre B, et al
     How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?
     Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33803.
     PubMed     Abstract available
     
     
     
153. SARINK D, White KK, Loo LWM, Wu AH, et al
     Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the Multiethnic Cohort Study.
     Int J Cancer. 2021 Sep 6. doi: 10.1002/ijc.33795.
     PubMed     Abstract available
     
     
     
154. COLE SE, John EM, Hines LM, Phipps AI, et al
     Cumulative menstrual months and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities (BEM) Study.
     Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33791.
     PubMed     Abstract available
     
     
     August 2021
155. MEEGDES M, Geurts SME, Erdkamp FLG, Dercksen MW, et al
     The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR+/HER2- advanced breast cancer patients: A study of the Dutch SONABRE Registry.
     Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33785.
     PubMed     Abstract available
     
     
     
156. EVANS DG, van Veen EM, Byers H, Roberts E, et al
     The importance of Ethnicity: are breast cancer Polygenic Risk Scores ready for women who are not of white European origin?
     Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33782.
     PubMed     Abstract available
     
     
     
157. ZHENG KH, Zhu K, Wactawski-Wende J, Freudenheim JL, et al
     Caffeine Intake from Coffee and Tea and Invasive Breast Cancer Incidence among Postmenopausal Women in the Women's Health Initiative.
     Int J Cancer. 2021 Aug 21. doi: 10.1002/ijc.33771.
     PubMed     Abstract available
     
     
     July 2021
158. CYRUS K, Wang Q, Sharawi Z, Noguchi G, et al
     Role of calcium in hormone independent and resistant breast cancer.
     Int J Cancer. 2021 Jul 21. doi: 10.1002/ijc.33745.
     PubMed     Abstract available
     
     
     
159. JANSANA A, Poblador-Plou B, Gimeno-Miguel A, Lanzuela M, et al
     Multimorbidity clusters among long-term breast cancer survivors in Spain: Results of the SURBCAN Study.
     Int J Cancer. 2021 Jul 13. doi: 10.1002/ijc.33736.
     PubMed     Abstract available
     
     
     
160. ZHANG L, Zhou M, Liu Y, Du F, et al
     Is It Beneficial for Patients with pT1-2N1M0 Breast Cancer to Receive Post-Mastectomy Radiotherapy? An Analysis Based on RecurIndex Assay.
     Int J Cancer. 2021 Jul 5. doi: 10.1002/ijc.33730.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Dermatology is free of charge.